HIV and HBV Co-infection - More Potency, More Policy

Introduction

Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence exceeds that of HIV and is estimated at 2 billion infected individuals worldwide, accounting for approximately 5% of the world’s population. 

Scope

Key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population 

Overview of the limitations surrounding co-morbid management such as recognition of co infection, high-risk groups and lack of efficacious antivirals 

Report Highlights

Concurrent early diagnosis of both HIV and HBV disease states is pivotal to increasing the lifespan of this co-morbid population. Effective treatment is currently hampered by poor patient compliance, HAART hepatotoxicity and lack of comprehensive treatment guidelines. 

Reasons to Purchase

Effectively target this niche sector, through a complete understanding of the prevalence of the co-morbid population in the seven major markets 

Identify the most promising products in the HIV and HBV pipelines, and track how current players are seeking to optimize their market share 

Scope

Analysis based on interviews with key opinion leaders in the major markets 

Report Highlights

Lack of potency with current HBV therapeutics is an obvious gap in treating both mono and co-infected patients currently being addressed by companies such as Gilead and Idenix/Novartis. 

Commercial support for global implementation of HBV vaccination need not preclude a high volume/low cost business model for a new potent HBV antiviral. 

January 2004, 89 pages 

Publisher: Datamonitor Infectious Diseases Reports 2004 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Infectious_Diseases_Reports_2004.html#a552